Skip to content
10-K

Annual Report

NEKTAR THERAPEUTICS NKTR

0001193125-26-104547

← back to feed
Filed
Mar 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 11, 2026 28.69M sh
Shares Diluted FY 2025 · Dec 31, 2025 16.87M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 13.71M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $0
Stock Repurchased FY 2025 · Dec 31, 2024 $3M
Capex FY 2025 · Dec 31, 2025 $171K
Capex FY 2025 · Dec 31, 2024 $1.47M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$208.51M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$175.71M
Cash And Equivalents FY 2025 · Dec 31, 2025 $15.12M
Cash And Equivalents FY 2025 · Dec 31, 2024 $44.25M
Stockholders Equity FY 2025 · Dec 31, 2025 $89.83M
Stockholders Equity FY 2025 · Dec 31, 2024 $60.74M
Stockholders Equity FY 2025 · Dec 31, 2023 $130.99M
Current Liabilities FY 2025 · Dec 31, 2025 $53.54M
Current Liabilities FY 2025 · Dec 31, 2024 $61.4M
Total Liabilities FY 2025 · Dec 31, 2025 $190.57M
Total Liabilities FY 2025 · Dec 31, 2024 $243.11M
Current Assets FY 2025 · Dec 31, 2025 $266.27M
Current Assets FY 2025 · Dec 31, 2024 $261.29M
Total Assets FY 2025 · Dec 31, 2025 $280.41M
Total Assets FY 2025 · Dec 31, 2024 $303.85M
Eps Diluted FY 2025 · Dec 31, 2025 −$9.73
Eps Diluted restated FY 2025 · Dec 31, 2024 −$8.68
Eps Basic FY 2025 · Dec 31, 2025 −$9.73
Eps Basic restated FY 2025 · Dec 31, 2024 −$8.68
Sga Expense FY 2025 · Dec 31, 2025 $68.67M
Sga Expense FY 2025 · Dec 31, 2024 $76.75M
Rd Expense FY 2025 · Dec 31, 2025 $117.33M
Rd Expense FY 2025 · Dec 31, 2024 $120.91M
Net Income FY 2025 · Dec 31, 2025 −$164.08M
Net Income FY 2025 · Dec 31, 2024 −$118.96M
Operating Income FY 2025 · Dec 31, 2025 −$140.1M
Operating Income FY 2025 · Dec 31, 2024 −$105.2M
Cost Of Revenue FY 2025 · Dec 31, 2025 $0
Cost Of Revenue FY 2025 · Dec 31, 2024 $30.69M
Revenue FY 2025 · Dec 31, 2025 $55.23M
Revenue FY 2025 · Dec 31, 2024 $98.43M